As we previously highlighted major alterations of circulating and tumor-infiltrating DCs’ features in melanoma patients, we further explored whether CLR expression profiles on DC subsets correlated with DCs’ activation status and functionality in melanoma patients. This evidence concerns the gene DCLK3 and melanoma.